Evidence map›Paper›PMID 34897996›Full record

ArticleCNS neuroscience & therapeutics2022

SerpinA3N attenuates ischemic stroke injury by reducing apoptosis and neuroinflammation.

Yu Zhang, Qianbo Chen, Dashuang Chen, Wenqi Zhao, Haowei Wang, Mei Yang, Zhenghua Xiang, Hongbin Yuan

Open access · goldAbstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Dying oligodendrocytes persist without mitochondria.bioRxiv : the preprint server for biology · 2026
    Article
  7. Article
  8. Article
  9. Gallic Acid Alleviates Cerebral Ischemia-reperfusion Injury in Mice by Mediating Microglial Polarization Through the NLRP3/mTOR Axis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Novel purine derivatives mitigate hypoxia ischemia related brain injury through agrin, zyxin and synaptotagmin proteins.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. PANoptosis: a potential target of atherosclerotic cardiovascular disease.Apoptosis : an international journal on programmed cell death · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yu ZhangDepartment of Anesthesiology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Qianbo ChenDepartment of Anesthesiology, Third Affiliated Hospital of Naval Medical University, Shanghai, China.
Dashuang ChenDepartment of Anesthesiology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Wenqi ZhaoDepartment of Anesthesiology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Haowei WangDepartment of Anesthesiology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Mei YangDepartment of Anesthesiology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Zhenghua XiangDepartment of Neurobiology, Key Laboratory of Molecular Neurobiology, Ministry of Education, Naval Medical University, Shanghai, China.
Hongbin YuanDepartment of Anesthesiology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.ORCID 0000-0001-8468-4005
Shanghai Changzheng Hospital · CNMinistry of Education of the People's Republic of China · CNShanghai Third People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the effect of serine protein inhibitor A3N (serpinA3N) in ischemic stroke and to explore its mechanism of action.

methodsMouse ischemic stroke model was induced by transient middle cerebral artery occlusion followed by reperfusion. The expression pattern of serpinA3N was assessed using immunofluorescence, Western blot analysis, and real-time quantitative PCR. An adeno-associated virus (AAV) and recombinant serpinA3N were administered. Additionally, co-immunoprecipitation-mass spectrometry and immunofluorescence co-staining were used to identify protein interactions.

resultsSerpinA3N was upregulated in astrocytes and neurons within the ischemic penumbra after stroke in the acute phase. The expression of serpinA3N gradually increased 6 h after reperfusion, peaked on the day 2-3, and then decreased by day 7. Overexpression of serpinA3N by AAV significantly reduced the infarct size and improved motor function, associated with alleviated inflammation and oxidative stress. SerpinA3N treatment also reduced apoptosis both in vivo and in vitro. Co-immunoprecipitation-mass spectrometry and Western blotting revealed that clusterin interacts with serpinA3N, and Akt-mTOR pathway members were upregulated by serpinA3N both in vivo and in vitro.

conclusionsSerpinA3N is expressed in astrocytes and penumbra neurons after stroke in mice. It reduces brain damage possibly via interacting with clusterin and inhibiting neuronal apoptosis and neuroinflammation.

Indexed as

Brain IschemiaIschemic StrokeReperfusion InjurySerpinsStrokeAcute-Phase ProteinsAnimalsApoptosisClusterinMiceNeuroinflammatory DiseasesAcute-Phase ProteinsClusterinSerpina3n protein, mouseSerpinsAAVAktclusterinoxidative stress

Identifiers

PMID34897996
PMCPMC8928918
OpenAlexW4200106549

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.